ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,747.85
0.03%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) News

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIRX
DateTimeSourceHeadlineSymbolCompany
31/05/202421:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
30/05/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/05/202421:05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
16/05/202421:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
16/05/202421:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/05/202421:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
14/05/202412:00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
09/05/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
09/05/202421:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
09/05/202421:05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/05/202421:05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
15/04/202413:00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
01/04/202413:30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
07/03/202422:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
07/03/202421:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
07/03/202421:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
07/03/202421:05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
29/02/202413:00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
28/02/202401:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202400:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202400:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/02/202402:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
06/02/202421:05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
04/01/202413:00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
12/12/202313:00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
04/12/202321:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
04/12/202313:30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
29/11/202300:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
29/11/202300:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/11/202322:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

Your Recent History

NYSE
RRC
Range Resources
NASDAQI
QUSOI
Credit Suisse Nasdaq WTI...
USOTC
CRMWF
Cromwell European Real E... (PK)
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved